Disitamab vedotin
- Generic Name
- Disitamab vedotin
- Drug Type
- Biotech
- CAS Number
- 2136633-23-1
- Unique Ingredient Identifier
- RB3U3A1S27
- Background
Disitamab vedotin is an antibody-drug conjugate drug targeting human epidermal growth factor receptor 2 (HER2). It is currently being investigated for cancers.
- Indication
用于至少接受过2个系统化疗的HER2过表达局部晚期或转移性胃癌（包括胃食管结合部腺癌）的患者，HER2过表达定义为HER2免疫组织化学检查结果为2+或3+。
RC48-ADC Combinatioed Envolizumab in Locally Advanced or Metastatic Biliary Tract Cancer With Positive HER-2
- First Posted Date
- 2022-06-14
- Last Posted Date
- 2022-06-14
- Lead Sponsor
- Jiangsu Cancer Institute & Hospital
- Target Recruit Count
- 29
- Registration Number
- NCT05417230
RC48-ADC Combined With S-1 for First-line Treatment of Advanced Gastroesophageal Adenocarcinoma With Moderate Expression of HER2
- Conditions
- Advanced Gastroesophageal Adenocarcinoma
- Interventions
- First Posted Date
- 2022-06-03
- Last Posted Date
- 2024-01-08
- Lead Sponsor
- Chinese PLA General Hospital
- Target Recruit Count
- 42
- Registration Number
- NCT05403242
- Locations
- 🇨🇳
Chinese PLA General Hospital, Beijing, China
🇨🇳Beijing Friendship Hospital, Beijing, China
Pembrolizumab and Disitamab Vedotin in HER2-expressing Metastatic Colorectal Cancer
- Conditions
- Colorectal Neoplasms
- Interventions
- First Posted Date
- 2022-04-19
- Last Posted Date
- 2022-04-20
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT05333809
A Study of RC48-ADC for the Treatment of HER2-expression Metastatic Breast Cancer With Abnormal Activation of PAM Pathway
- First Posted Date
- 2022-04-15
- Last Posted Date
- 2022-04-15
- Target Recruit Count
- 64
- Registration Number
- NCT05331326
- Locations
- 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳Beijing Huanxing Cancer Hospital, Beijing, Beijing, China
🇨🇳Cancer Hospital, Chinese Academy of Medical Sciences, Hebei Center, Langfang, Hebei, China
A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma
- Conditions
- Urothelial CarcinomaHER2-expressing
- Interventions
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2023-12-18
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 452
- Registration Number
- NCT05302284
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, China
🇨🇳Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
A Study of RC48-ADC Combined With JS001 For Perioperative Treatment of Muscle-Invasive Bladder Cancer
- First Posted Date
- 2022-03-28
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT05297552
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Peking University First Hospital, Beijing, Beijing, China
A Study of RC48-ADC in Advanced Melanoma Subjects With HER2 Variant (Mutation, Amplification, Overexpression)
- Conditions
- Advanced MelanomaMelanoma, Stage IIHER2-positive
- Interventions
- First Posted Date
- 2021-11-26
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT05135715
- Locations
- 🇨🇳
The First Hospital of Jilin University, Changchun, Jilin, China
🇨🇳Zhejiang cancer hospital, Hangzhou, Zhejiang, China
🇨🇳Beijing Cancer Hospital, Beijing, China
A Clinical Study of RC48-ADC Combined With Triplizumab For Treatment of Myometrial Invasive Bladder Cancer
- First Posted Date
- 2021-08-23
- Last Posted Date
- 2021-08-23
- Lead Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- Target Recruit Count
- 25
- Registration Number
- NCT05016973
- Locations
- 🇨🇳
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China
A Study of RC48-ADC for the Treatment of HER2-expressing Gynecological Malignancies
- First Posted Date
- 2021-07-16
- Last Posted Date
- 2023-12-18
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT04965519
- Locations
- 🇨🇳
Chinese Academy of Medical Sciences Cancer Hospital, Beijing, Beijing, China
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
- Conditions
- Urothelial Carcinoma
- Interventions
- First Posted Date
- 2021-05-10
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 372
- Registration Number
- NCT04879329
- Locations
- 🇦🇷
Clinica Viedma, Viedma, Argentina
🇦🇺Lyell McEwin Hospital, Elizabeth Vale, Other, Australia
🇦🇺Macquarie University Hospital, New South Whales, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.